Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will take part in multiple investor conferences and fireside chats in early March 2026, including TD Cowen (March 3), UBS Biotech Summit (March 9), Leerink (March 10), Jefferies Biotech on the Beach (March 11), and Barclays (March 12).
Live webcasts of each presentation will be available under News and Events in the Investors section of the company website, with replays archived after the events.
Details
News Market Reaction – KYMR
On Feb 24, the day this news came out, KYMR closed 2.92% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- TD Cowen conference time
- March 3 at 9:10 a.m. ET
- TD Cowen 46th Annual Healthcare Conference fireside chat
- Leerink conference time
- March 10 at 11:20 a.m. ET
- Leerink Partners Global Healthcare Conference fireside chat
- Barclays conference time
- March 12 at 9:30 a.m. ET
- Barclays 28th Annual Global Healthcare Conference fireside chat
- UBS summit date
- March 9
- UBS Biotech Summit Miami participation
- Jefferies summit date
- March 11
- Jefferies Biotech on the Beach Summit participation
Historical Context
-
Announced date and webcast details for Q4 and full-year 2025 results.
-
Participation in February 2026 investor fireside chats and related webcasts.
-
First patient dosed in BREADTH Phase 2b asthma trial of KT-621.
-
Outlined 2026 objectives and reported an estimated $1.6B cash runway.
-
Previewed J.P. Morgan Healthcare Conference presentation and webcast access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
- TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;
- Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; and
- Barclays 28th Annual Global Healthcare Conference in Miami, FL on March 12 at 9:30 a.m. ET.
In addition, the Company will participate in the UBS Biotech Summit Miami and Jefferies Biotech on the Beach Summit on March 9 and March 11, respectively.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
Vice President, Corporate Communications
mhenson@kymeratx.com
857-285-5300
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.